Humanized anti-c5 antibodies and uses thereof
AssigneesThe Trustees of the University of Pennsylvania, Kira Pharmaceuticals (US) LLC
InventorsWenchao Song, Takashi Miwa, Damodar Gullipalli, Ping Tsui, Sayaka Sato
Life of this patent
Estimating the term…
Abstract
This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.
Claims27
A pH dependent antibody that specifically binds to human C5, wherein the pH dependent antibody comprises at least one CDR selected from the group consisting of:
- a VH-CDR1 comprising a variant of SEQ ID NO:
- 3 having at least one substitution relative to SEQ ID NO:
- 3;
- a VH-CDR2 comprising a variant of SEQ ID NO:
- 4 having at least one substitution relative to SEQ ID NO:
- 4, a VH-CDR3 comprising a variant of SEQ ID NO:
- 5 having at least one substitution relative to SEQ ID NO:
- 5;
- a VL-CDR1 comprising a variant of SEQ ID NO:
- 8 having at least one substitution relative to SEQ ID NO:
- 8;
- a VL-CDR2 comprising a variant of SEQ ID NO:
- 9 having at least one substitution relative to SEQ ID NO:
- 9;
- and a VL-CDR3 comprising a variant of SEQ ID NO:
- 10 having at least one substitution relative to SEQ ID NO:
- 10.
-7. (canceled)
-49. (canceled)
-58. (canceled)
-63. (canceled)
(canceled)
A genetically modified non-human animal that expresses human C5.
(canceled)
(canceled)
Dependencies are inferred from the claim text.